Lymphoma News Archives | Page 2 of 5 | Lymphoma Research Foundation

U.S. Food and Drug Administration Approves Ibrutinib (IMBRUVICA) Plus Rituximab (RITUXAN) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

This approval expands the use of acalabrutinib, which received accelerated approval from the FDA for the treatment of adult patients with mantle cell lymphoma (MCL).

COVID-19 Lymphoma News

Physical Activity and Exercise While Sheltering at Home

This article was contributed by Oncology Dietitian and Clinical Exercise Physiologist, Hannah Manella, MS, RD, LDN, ACSM-CEP, CET (Rush University Cancer Center). There is no

COVID-19 Lymphoma News

Creating a Routine That’s Right for You During COVID-19

This article was contributed by mindfulness-based leadership coach and inspirational speaker, Amy Jin. Humans are creatures of habit, and routines can offer mental health benefits,

COVID-19 Lymphoma News

5 Mindfulness Tips to Get Through COVID-19

This article was contributed by mindfulness-based leadership coach and inspirational speaker, Amy Jin. Chances are, you’re reading this at home, where you’ve been social distancing

COVID-19 Lymphoma News

COVID-19: Tips for Eating Healthy While Social Distancing

This article was contributed by Oncology Dietitian and Clinical Exercise Physiologist, Hannah Manella, MS, RD, LDN, ACSM-CEP, CET (Rush University Cancer Center). There is no

COVID-19 Lymphoma News

Understanding COVID-19/Novel Coronavirus: What Lymphoma Patients Need to Know

What is COVID-19/coronavirus disease? The novel SARS-CoV-2 coronavirus that has recently been in the news is a virus that has not been previously identified. The

Lymphoma News

Patient Perspectives: Study Explores Unmet Needs of Lymphoma Patients and Caregivers

Due to an increase in new and effective treatments, outcomes among lymphoma patients have improved, with a 10-year survival rate reported to be higher than

Lymphoma News

Understanding Cancer-Related Financial Toxicity

Cancer is one of the costliest conditions to treat today in the United States. With outcomes among patients with lymphoma improving, managing costs related to

Lymphoma News

U.S. Food and Drug Administration Approves Acalabrutinib (CALQUENCE) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

This approval expands the use of acalabrutinib, which received accelerated approval from the FDA for the treatment of adult patients with mantle cell lymphoma (MCL).

Lymphoma News

U.S. Food and Drug Administration Approves Zanubrutinib (BRUKINSA) for Mantle Cell Lymphoma (MCL)

The U.S. Food and Drug Administration (FDA) announced it has approved the use of zanubrutinib (BRUKINSA, BeiGene, Ltd.) for adult patients with mantle cell lymphoma (MCL) who have received at least on prior therapy.